The TruSight Oncology in vitro diagnostic (IVD) test is being launched first in Europe and according to Illumina’s cancer head Kevin Keegan can match patients with suitable therapies “according to clinical guidelines or clinical trials, based on their tumour profile.”
The kit looks for more than 500 cancer-relevant genes across 30 solid tumour types, and the technology behind it has been in use for some time as a cancer research tool, with hundreds of labs around the world using it in their studies.
The launch of a clinical version of the test could make it easier for patients to gain access to targeted cancer therapies, according to Illumina.
